At the last check on Thursday, Acer Therapeutics Inc.’s (NASDAQ:ACER) stock was up $0.78, moving up 127.87 percent to $1.39. The average number of shares traded per day over the past five days has been 21,544,984 shares. 3 times new highs have been achieved over the past 5 days, with a $0.7610 gain in that time frame. In the last twenty days, the average volume was 5,475,781, while in the previous 50 days, it was 2,250,714.
Since last month, ACER stock rose 68.69%. Shares of the company fell to $0.5515 on 08/25/23, the lowest level in the past month. A 52-week high of $4.56 was reached on 01/12/23 after having rallying from a 52-week low of $0.55. Since the beginning of this year, ACER’s stock price has dropped by -44.62% or -$1.1500, and marked a new high 6 times. However, the stock has declined by -69.52% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
ACER stock investors should be aware that Acer Therapeutics Inc. (ACER) stock had its last reported insider trading activity 275 days ago on Nov 29. Schelling Chris, the President & CEO of the company, purchased of 819,672 shares for $1.22 on Nov 29. It resulted in a $1,000,000 investment by the insider. ASELAGE STEVE added 409,836 shares at an average price of $1.22 on Nov 29. The insider now owns 483,741 shares following the transaction.
Financial Health
Based on annual data, ACER earned $24.61 million in gross profit.
While analysts expected Acer Therapeutics Inc. to report -$0.25 quarterly earnings, the actual figure was -$0.33 per share, beating the consensus estimate by -32.00%. The liabilities of Acer Therapeutics Inc. were 47.9 million at the end of its most recent quarter ended June 29, and its total debt was $32.27 million. The value of shareholders’ equity is $24.46 million.
Technical Picture
This quick technical analysis looks at Acer Therapeutics Inc.’s (ACER) price momentum. With a historical volatility rate of 413.52%, the RSI 9-day stood at 82.74% on 30 August.
With respect to its five-day moving average, the current Acer Therapeutics Inc. price is up by +127.05% percent or $0.7610. At present, ACER shares trade +61.42% above its 20-day simple moving average and +46.65% percent above its 100-day simple moving average. However, the stock is currently trading approximately +51.43% above its SMA50 and +10.57% above its SMA200.
Stochastic coefficient K was 31.61% and Stochastic coefficient D was 18.81%, while ATR was 0.1959. Given the Stochastic reading of 66.90% for the 14-day period, the RSI (14) reading has been calculated as 76.20%. As of today, the MACD Oscillator reading stands at 0.1557, while the 14-day reading stands at 0.1316.
Analyst Ratings
H.C. Wainwright reiterated its a Buy rating on Acer Therapeutics Inc. (NASDAQ: ACER) in a note to investors. The analysts firm has however raised their price target to $10, representing a possible 97.47% increase in the stock price. Acer Therapeutics Inc. (ACER) has been rated Buy by analysts. According to 0 brokerage firms, ACER is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Acer Therapeutics Inc. stock as buy, with 1 recommending it as overweight.
With a median target price of $10.00, the current consensus forecast for the stock is $10.00 – $10.00. Based on these forecasts, analysts predict Acer Therapeutics Inc. (ACER) will achieve an average price target of $10.00.
